In today’s briefing:
- China Healthcare Weekly (May.19)- Decoupling Deadline with WuXi,Biotech Classification,Deals Cooling
- Bangkok Dusit Medical Services (BDMS TB): Thai and International Patients Drives 1Q24 Result
- McKesson Corporation: How Is The Revenue and Profit Growth Across Segments Expected To Evolve? – Major Drivers
- Teleflex Incorporated: Driving Durable Growth through Organic Growth Opportunities and Innovation! – Major Drivers
China Healthcare Weekly (May.19)- Decoupling Deadline with WuXi,Biotech Classification,Deals Cooling
- In 24Q1, the innovative drug projects and medical device projects ranked top two in domestic investment and financing deals, but investment in the field of AI cooled down.
- For biotech that located in China and only for China markets, it’s hard for them to generate good returns. It is recommended not to spend too much time on them.
- As the US House Committee advances the BIOSECURE Act to restrict WuXi AppTec/WuXi Bio last week, we listed some points worth the attention at this stage.This is far from over.
Bangkok Dusit Medical Services (BDMS TB): Thai and International Patients Drives 1Q24 Result
- Bangkok Dusit Medical Services (BDMS TB) posted double-digit growth revenue, EBITDA, and net profit in 1Q24. International and Thai patients reported revenue growth of 12% and 10%, YoY, respectively.
- EBITDA grew at a faster pace of 13% YoY to THB6.8B, due to tight cost control. Net profit of THB4.1B beat estimates.
- BDMS opened one secondary care hospital with 113 registered beds in March. Phuket Cancer Center is expected to start operation in 3Q24.
McKesson Corporation: How Is The Revenue and Profit Growth Across Segments Expected To Evolve? – Major Drivers
- McKesson Corporation’s Fourth Quarter Fiscal 2024 earnings reflect a strong financial year for the company with notable advancements throughout its strategic priorities.
- Consolidated revenue increased by 12% reaching $309 billion with adjusted earnings per diluted share increasing by 6% to $27.44 both exceeding the expectations set at the start of the fiscal year.
- The company achieved this growth across the enterprise with their differentiated portfolio of assets, innovative solutions, and commitment to quality and operational excellence.
Teleflex Incorporated: Driving Durable Growth through Organic Growth Opportunities and Innovation! – Major Drivers
- Teleflex Inc.’s Q1 2024 Earnings revealed promising initial results, led by Liam Kelly, the Chairman, President and Chief Executive Officer, along with Thomas Powell, the Executive Vice President, and Chief Financial Officer.
- For Q1 2024, Teleflex achieved revenues of $737.8 million, a 3.8% YoY increase on a GAAP and constant currency basis.
- Utilization of the company’s products trend positively and was on par with expectations.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Data and News
- ✓ Events & Webinars
